Attovia Therapeutics, Inc. (ATTO) Stock Ticker
ATTO right now
Market factors today
Unlock the full ATTO picture
About Attovia Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
ATTO stock facts
| Ticker symbol | ATTO |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $765.1M |
| CEO | Tao Fu |
| Employees | 44 |
| Headquarters | San Carlos, CA, US |
| IPO date | 2026-08-05 |
| Website | www.attovia.com |
What you can see for ATTO on Tickr
Live ATTO price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ATTO report.
Rankings
FAQ
What is the ticker symbol for Attovia Therapeutics, Inc.?
The ticker symbol for Attovia Therapeutics, Inc. is ATTO, listed on the NASDAQ.
What is ATTO?
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory…